Transthyretin Amyloidosis, or ATTR, is considered a single disease, however the diversity in its clinical presentation is staggering. In this blog, we’ll discuss some of the most common hereditary variants and how the disease manifestation differs around the world in documented hotspots.
What Is Amyloidosis
CRISPR/Cas9 – ATTR Clinical Trial Update
Per the National Institute of Health, “One of the most promising areas of research in recent years has been gene editing, including CRISPR/Cas9, for fixing misspellings in genes to treat or even cure many conditions.” In this piece we provide a clinical trial update for transthyretin (TTR) amyloidosis using this technology.
Heart Failure & Amyloidosis
Heart failure occurs when the heart muscle doesn’t pump blood as well as it should. Many medical conditions that damage the heart muscle can cause heart failure, such as Coronary artery disease, Heart attack, Obesity, Kidney disease, Diabetes, and Cardiomyopathy. Here we summarize how cardiac amyloidosis is associated with heart failure.
FDA Drug Approval Process
Carpal Tunnel & Amyloidosis – An Update
In the amyloidosis community, we are quickly learning that carpal tunnel syndrome can be one of the earliest symptoms/indicators of amyloidosis, sometimes presenting up to a decade before diagnosis. In addition, it is suspected that amyloidosis is not as rare as we once thought. Interestingly, carpal tunnel release surgery is helping to illustrate just that.